Nov 5, 2020 · Modified RVD-lite is one of the appropriate therapeutic options, in the transplant-ineligible multiple myeloma patients. Twenty-five percent of patients with cardiac amyloidosis …

May 29, 2019 · Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We …

Subcutaneous route of administration of daratumumab uses fixed dosing and is the standard of care for patients. The intravenous route of administration uses weight-based dosing (Refer to …

Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with …

Aug 20, 2020 · Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients …

Dec 12, 2023 · Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined …

Multiple guidelines recommend DRd, DVMP, and RVD as first-line treatment options for TIE-NDMM (4, 11). However, no randomized controlled trials have directly compared the efficacy …

Nov 5, 2024 · The dual primary objectives are (A) to compare progression free survival (PFS) between cohorts 1 (VRd-Lite) and 2 (DRd-R); (B) to compare overall survival (OS) between …

With DRd, however, the daratumumab-based triplet is continued monthly until progression, for perhaps 5 or 6 years. Some considerations for choice of initial therapy relates to the baseline …

Sep 27, 2021 · The primary endpoint of the RVd-lite study was overall response rate (ORR) after 4 cycles of therapy. The ORR was 86% for the 50 patients, 66% of whom achieved a very …